Madrigal Pharmaceuticals Inc. (NASDAQ:MDGL) and Akcea Therapeutics Inc. (NASDAQ:AKCA) are two firms in the Biotechnology that compete against each other. Below is a comparison of their risk, analyst recommendations, profitability, institutional ownership, dividends, earnings and valuation.

Valuation & Earnings

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Madrigal Pharmaceuticals Inc.	N/A	0.00	32.81M	-2.13	0.00
Akcea Therapeutics Inc.	64.87M	41.09	233.61M	-2.28	0.00

We can see in table 1 the earnings per share (EPS), gross revenue and valuation of Madrigal Pharmaceuticals Inc. and Akcea Therapeutics Inc.

Profitability

Table 2 provides Madrigal Pharmaceuticals Inc. and Akcea Therapeutics Inc.’s return on equity, return on assets and net margins.

	Net Margins	Return on Equity	Return on Assets
Madrigal Pharmaceuticals Inc.	0.00%	0%	0%
Akcea Therapeutics Inc.	-360.12%	-59.9%	-41%

Liquidity

The current Quick Ratio of Madrigal Pharmaceuticals Inc. is 57.5 while its Current Ratio is 57.5. Meanwhile, Akcea Therapeutics Inc. has a Current Ratio of 3.6 while its Quick Ratio is 3.6. Madrigal Pharmaceuticals Inc. is better positioned to pay off its short-term and long-term debts than Akcea Therapeutics Inc.

Insider and Institutional Ownership

Institutional investors owned 95.7% of Madrigal Pharmaceuticals Inc. shares and 26.5% of Akcea Therapeutics Inc. shares. About 3.2% of Madrigal Pharmaceuticals Inc.’s share are owned by insiders. Competitively, Akcea Therapeutics Inc. has 75.5% of it’s share owned by insiders.

Performance

In this table we provide the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

	Performance (W)	Performance (M)	Performance (Q)	Performance (HY)	Performance (Y)	Performance (YTD)
Madrigal Pharmaceuticals Inc.	1.75%	19.8%	20.7%	-42.37%	11.43%	23.03%
Akcea Therapeutics Inc.	0.47%	20.62%	-2.38%	27.07%	88.92%	6.37%

For the past year Madrigal Pharmaceuticals Inc. has stronger performance than Akcea Therapeutics Inc.

Summary

On 7 of the 9 factors Madrigal Pharmaceuticals Inc. beats Akcea Therapeutics Inc.

Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic candidates for the treatment of cardiovascular, metabolic, and liver diseases. The company’s lead candidate is MGL-3196, which is in Phase II clinical trials, a liver-directed thyroid hormone receptor-ß (THR-ß) agonist used for the treatment of nonalcoholic fatty liver disease, nonalcoholic steatohepatitis, and familial hypercholesterolemia. It is also developing MGL-3745, which is in pre-clinical stage, a THR-ß agonist that is in preclinical trials. The company was founded in 2011 and is headquartered in West Conshohocken, Pennsylvania.

Akcea Therapeutics Inc., a late-stage biopharmaceutical company, focuses on developing and commercializing drugs to treat patients with cardiometabolic diseases caused by lipid disorders in the United States and internationally. It develops Volanesorsen, which has completed Phase 3 clinical study for the treatment of familial chylomicronemia syndrome; and that is in Phase 3 clinical study for the treatment of familial partial lipodystrophy. The company also develops AKCEA-APO(a)-LRx, which has completed Phase 2b clinical study for treating patients suffering with hyperlipoproteinemia; AKCEA-ANGPTL3-LRx that has completed Phase 1/2 clinical study for the treatment of multiple lipid disorders; and AKCEA-APOCIII-LRx, which is in Phase 1/2 study for the treatment of cardiovascular disease driven by high triglycerides. It has strategic collaboration with Novartis Pharma AG. The company was incorporated in 2014 and is headquartered in Cambridge, Massachusetts. Akcea Therapeutics Inc. is a subsidiary of Ionis Pharmaceuticals, Inc.